Kevin Talbot

List of Publications by Year
in descending order

250 papers	19,259 citations	8181 76 h-index	14759 127 g-index
260 all docs	260 docs citations	260 times ranked	19717 citing authors

#	Article	IF	Citations
1	Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 75-81.	1.9	24
2	Human stem cell models of neurodegeneration: From basic science of amyotrophic lateral sclerosis to clinical translation. Cell Stem Cell, 2022, 29, 11-35.	11.1	39
3	Genetic testing in motor neurone disease. Practical Neurology, 2022, 22, 107-116.	1.1	17
4	Modeling seeding and neuroanatomic spread of pathology in amyotrophic lateral sclerosis. NeuroImage, 2022, 251, 118968.	4.2	5
5	Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. Brain Communications, 2022, 4, fcac029.	3.3	29
6	A case of SOD1 deficiency: implications for clinical trials. Brain, 2022, 145, 805-806.	7.6	3
7	Hyperexcitability in young iPSC-derived C9ORF72 mutant motor neurons is associated with increased intracellular calcium release. Scientific Reports, 2022, 12, 7378.	3.3	6
8	Creatine kinase and prognosis in amyotrophic lateral sclerosis: a literature review and multi-centre cohort analysis. Journal of Neurology, 2022, 269, 5395-5404.	3.6	6
9	Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron, 2021, 109, 448-460.e4.	8.1	56
10	Detection and quantification of novel Câ€terminal TDPâ€43 fragments in ALSâ€TDP. Brain Pathology, 2021, 31, e12923.	4.1	26
11	Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nature Reviews Neurology, 2021, 17, 104-118.	10.1	152
12	Motor Neuron Disease Register for England, Wales and Northern Irelandâ€"an analysis of incidence in England. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 86-93.	1.7	10
13	A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3. Cell Death and Disease, 2021, 12, 136.	6.3	8
14	Targeting the 5â€² untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy. Molecular Therapy - Nucleic Acids, 2021, 23, 731-742.	5.1	3
15	Network Analysis of the CSF Proteome Characterizes Convergent Pathways of Cellular Dysfunction in ALS. Frontiers in Neuroscience, 2021, 15, 642324.	2.8	6
16	Isolated homozygous R217X OPTN mutation causes knock-out of functional C-terminal optineurin domains and associated oligodendrogliopathy-dominant ALSâ€"TDP. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1022-1024.	1.9	2
17	Non-neuronal cells in amyotrophic lateral sclerosis â€" from pathogenesis to biomarkers. Nature Reviews Neurology, 2021, 17, 333-348.	10.1	78
18	The Role of Mitochondrial Dysfunction and ER Stress in TDP-43 and C9ORF72 ALS. Frontiers in Cellular Neuroscience, 2021, 15, 653688.	3.7	43

#	Article	IF	Citations
19	Axonal TDP-43 condensates drive neuromuscular junction disruption through inhibition of local synthesis of nuclear encoded mitochondrial proteins. Nature Communications, 2021, 12, 6914.	12.8	67
20	An ALS-linked mutation in TDP-43 disrupts normal protein interactions in the motor neuron response to oxidative stress. Neurobiology of Disease, 2020, 144, 105050.	4.4	30
21	Amyotrophic Lateral Sclerosis: network vulnerability and monosynaptic connections. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 906-906.	1.9	0
22	Quantitative patterns of motor cortex proteinopathy across ALS genotypes. Acta Neuropathologica Communications, 2020, 8, 98.	5.2	27
23	CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 1296-1306.	3.7	26
24	Amyotrophic lateral sclerosis with a heterozygous D91A SOD1 variant and classical ALS-TDP neuropathology. Neurology, 2020, 95, 595-596.	1.1	9
25	CSF extracellular vesicle proteomics demonstrates altered protein homeostasis in amyotrophic lateral sclerosis. Clinical Proteomics, 2020, 17, 31.	2.1	27
26	Neurotrophic Properties of C-Terminal Domain of the Heavy Chain of Tetanus Toxin on Motor Neuron Disease. Toxins, 2020, 12, 666.	3.4	2
27	The use of biotelemetry to explore disease progression markers in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 563-573.	1.7	12
28	Correction of amyotrophic lateral sclerosis related phenotypes in induced pluripotent stem cell-derived motor neurons carrying a hexanucleotide expansion mutation in C9orf72 by CRISPR/Cas9 genome editing using homology-directed repair. Human Molecular Genetics, 2020, 29, 2200-2217.	2.9	39
29	Mice Carrying ALS Mutant TDP-43, but Not Mutant FUS, Display InÂVivo Defects in Axonal Transport of Signaling Endosomes. Cell Reports, 2020, 30, 3655-3662.e2.	6.4	51
30	Primary lateral sclerosis: diagnosis and management. Practical Neurology, 2020, 20, 262-269.	1.1	19
31	Measuring quality of life in ALS/MND: validation of the WHOQOL-BREF. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 364-372.	1.7	5
32	Identification of a potential non-coding RNA biomarker signature for amyotrophic lateral sclerosis. Brain Communications, 2020, 2, fcaa053.	3.3	34
33	Regional callosal integrity and bilaterality of limb weakness in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 396-402.	1.7	13
34	Deep phenotyping of peripheral tissue facilitates mechanistic disease stratification in sporadic Parkinsonâ€™s disease. Progress in Neurobiology, 2020, 187, 101772.	5.7	35
35	Impairment of Mitochondrial Calcium Buffering Links Mutations in C9ORF72 and TARDBP in iPS-Derived Motor Neurons from Patients with ALS/FTD. Stem Cell Reports, 2020, 14, 892-908.	4.8	86
36	A proposal for new diagnostic criteria for ALS. Clinical Neurophysiology, 2020, 131, 1975-1978.	1.5	268

#	Article	IF	Citations
37	Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. Journal of Clinical Investigation, 2020, 130, 6080-6092.	8.2	117
38	Development of LNA Gapmer Oligonucleotide-Based Therapy for ALS/FTD Caused by the C9orf72 Repeat Expansion. Methods in Molecular Biology, 2020, 2176, 185-208.	0.9	1
39	Tracheostomy in motor neurone disease. Practical Neurology, 2019, 19, 467-475.	1.1	15
40	Wrangling RNA: Antisense oligonucleotides for neurological disorders. Science Translational Medicine, 2019, 11, .	12.4	11
41	Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis. Brain, 2019, 142, 586-605.	7.6	84
42	Cerebellar tract alterations in PLS and ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 281-284.	1.7	26
43	The relationships between symptoms, disability, perceived health and quality of life in amyotrophic lateral sclerosis/motor neuron disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 317-327.	1.7	27
44	CSF chitinase proteins in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1215-1220.	1.9	66
45	Neuronal over-expression of Oxr1 is protective against ALS-associated mutant TDP-43 mislocalisation in motor neurons and neuromuscular defects in vivo. Human Molecular Genetics, 2019, 28, 3584-3599.	2.9	19
46	Interaction of Axonal Chondrolectin with Collagen XIXa1 Is Necessary for Precise Neuromuscular Junction Formation. Cell Reports, 2019, 29, 1082-1098.e10.	6.4	13
47	Frequency and signature of somatic variants in 1461 human brain exomes. Genetics in Medicine, 2019, 21, 904-912.	2.4	20
48	Single-copy expression of an amyotrophic lateral sclerosis-linked TDP-43 mutation (M337V) in BAC transgenic mice leads to altered stress granule dynamics and progressive motor dysfunction. Neurobiology of Disease, 2019, 121, 148-162.	4.4	62
49	Objectively Monitoring Amyotrophic Lateral Sclerosis Patient Symptoms During Clinical Trials With Sensors: Observational Study. JMIR MHealth and UHealth, 2019, 7, e13433.	3.7	32
50	Towards a TDP-43-Based Biomarker for ALS and FTLD. Molecular Neurobiology, 2018, 55, 7789-7801.	4.0	100
51	Development and validation of Spasticity Index-Amyotrophic Lateral Sclerosis. Acta Neurologica Scandinavica, 2018, 138, 47-54.	2.1	7
52	Increased cerebral functional connectivity in ALS. Neurology, 2018, 90, e1418-e1424.	1.1	26
53	Impaired corticomuscular and interhemispheric cortical beta oscillation coupling in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2018, 129, 1479-1489.	1.5	36
54	Advances in therapy for spinal muscular atrophy: promises and challenges. Nature Reviews Neurology, 2018, 14, 214-224.	10.1	174

#	Article	IF	Citations
55	HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease. Brain, 2018, 141, 673-687.	7.6	93
56	The two-year progression of structural and functional cerebral MRI in amyotrophic lateral sclerosis. NeuroImage: Clinical, 2018, 17, 953-961.	2.7	100
57	Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Annals of Neurology, 2018, 83, 258-268.	5.3	107
58	Oligogenic genetic variation of neurodegenerative disease genes in 980 postmortem human brains. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 813-816.	1.9	17
59	Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurology, The, 2018, 17, 423-433.	10.2	342
60	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
61	UFLCâ€Derived CSF Extracellular Vesicle Origin and Proteome. Proteomics, 2018, 18, e1800257.	2.2	36
62	Neurodegeneration in SCA14 is associated with increased PKCÎ³ kinase activity, mislocalization and aggregation. Acta Neuropathologica Communications, 2018, 6, 99.	5.2	37
63	ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function. Neurobiology of Aging, 2018, 71, 266.e1-266.e10.	3.1	59
64	Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis. EBioMedicine, 2018, 33, 169-184.	6.1	17
65	Regional thalamic MRI as a marker of widespread cortical pathology and progressive frontotemporal involvement in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1250-1258.	1.9	39
66	Amyotrophic lateral sclerosis: the complex path to precision medicine. Journal of Neurology, 2018, 265, 2454-2462.	3.6	36
67	Sweet food preference in amyotrophic lateral sclerosis. Practical Neurology, 2017, 17, 128-129.	1.1	4
68	A risk stratifying tool to facilitate safe late-stage percutaneous endoscopic gastrostomy in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 243-248.	1.7	18
69	ADCY5-related dyskinesia presenting as familial myoclonus-dystonia. Neurogenetics, 2017, 18, 111-117.	1.4	31
70	Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains. Acta Neuropathologica Communications, 2017, 5, 13.	5.2	83
71	Whole-exome sequencing of 228 patients with sporadic Parkinsonâ€™s disease. Scientific Reports, 2017, 7, 41188.	3.3	27
72	Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	12.4	129

#	Article	IF	Citations
73	The SMA Trust: the role of a disease-focused research charity in developing treatments for SMA. Gene Therapy, 2017, 24, 544-546.	4.5	8
74	C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. Brain, 2017, 140, 887-897.	7.6	126
75	Trk receptor signaling and sensory neuron fate are perturbed in human neuropathy caused by Gars mutations. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E3324-E3333.	7.1	61
76	Genetic compendium of 1511 human brains available through the UK Medical Research Council Brain Banks Network Resource. Genome Research, 2017, 27, 165-173.	5.5	44
77	July 2017 ENCALS statement on edaravone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 471-474.	1.7	41
78	Therapeutic strategies for spinal muscular atrophy: SMN and beyond. DMM Disease Models and Mechanisms, 2017, 10, 943-954.	2.4	87
79	Fundus fluorescein angiography in Susacâ€™s syndrome. Practical Neurology, 2017, 17, 472-473.	1.1	1
80	Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape. Human Molecular Genetics, 2017, 26, R151-R159.	2.9	61
81	The clinical landscape for SMA in a new therapeutic era. Gene Therapy, 2017, 24, 529-533.	4.5	133
82	Genetic screening in sporadic ALS and FTD. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1042-1044.	1.9	105
83	Defective cholesterol metabolism in amyotrophic lateral sclerosis. Journal of Lipid Research, 2017, 58, 267-278.	4.2	115
84	A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 1-9.	1.7	20
85	Altered cortical betaâ€band oscillations reflect motor system degeneration in amyotrophic lateral sclerosis. Human Brain Mapping, 2017, 38, 237-254.	3.6	58
86	Excessive burden of lysosomal storage disorder gene variants in Parkinsonâ€™s disease. Brain, 2017, 140, 3191-3203.	7.6	323
87	Quantitative FLAIR MRI in Amyotrophic Lateral Sclerosis. Academic Radiology, 2017, 24, 1187-1194.	2.5	31
88	ABN news. Practical Neurology, 2016, 16, 171-171.	1.1	0
89	Vascular <scp>D</scp>efects and <scp>S</scp>pinal <scp>C</scp>ord <scp>H</scp>ypoxia in <scp>S</scp>pinal <scp>M</scp>uscular <scp>A</scp>trophy. Annals of Neurology, 2016, 79, 217-230.	5.3	79
90	Clinical tool for predicting survival in ALS: do we need one?. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1275-1275.	1.9	4

#	Article	IF	Citations
91	What is the role of TDP-43 inC9orf72-related amyotrophic lateral sclerosis and frontemporal dementia?. Brain, 2016, 139, 3057-3059.	7.6	7
92	Increased functional connectivity common to symptomatic amyotrophic lateral sclerosis and those at genetic risk. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 580-588.	1.9	82
93	Extracellular vesicles in neurodegenerative disease â€" pathogenesis to biomarkers. Nature Reviews Neurology, 2016, 12, 346-357.	10.1	299
94	Pathogenesis of FUS-associated ALS and FTD: insights from rodent models. Acta Neuropathologica Communications, 2016, 4, 99.	5.2	97
95	C9orf72 Hexanucleotide Expansions Are Associated with Altered Endoplasmic Reticulum Calcium Homeostasis and Stress Granule Formation in Induced Pluripotent Stem Cell-Derived Neurons from Patients with Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Stem Cells, 2016, 34, 2063-2078.	3.2	195
96	Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10962-10967.	7.1	159
97	Nutritional pathway for people with motor neurone disease. British Journal of Community Nursing, 2016, 21, 360-363.	0.4	1
98	NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1037-1042.	21.4	218
99	Psychiatric disorders prior to amyotrophic lateral sclerosis. Annals of Neurology, 2016, 80, 935-938.	5.3	49
100	Cerebrovascular injury as a risk factor for amyotrophic lateral sclerosis: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 244-246.	1.9	31
101	The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 414-425.	1.7	65
102	ER Stress and Autophagic Perturbations Lead to Elevated Extracellular Î±-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons. Stem Cell Reports, 2016, 6, 342-356.	4.8	279
103	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. American Journal of Human Genetics, 2016, 98, 500-513.	6.2	333
104	Eye-tracking in amyotrophic lateral sclerosis: A longitudinal study of saccadic and cognitive tasks. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 101-111.	1.7	65
105	DiPALS: Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis â€" a randomised controlled trial. Health Technology Assessment, 2016, 20, 1-186.	2.8	13
106	Identification of distinct circulating exosomes in Parkinson's disease. Annals of Clinical and Translational Neurology, 2015, 2, 353-361.	3.7	111
107	<scp>CSF</scp> neurofilament light chain reflects corticospinal tract degeneration in <scp>ALS</scp>. Annals of Clinical and Translational Neurology, 2015, 2, 748-755.	3.7	118
108	Motor neuron disease: current management and future prospects. Internal Medicine Journal, 2015, 45, 1005-1013.	0.8	18

#	Article	IF	Citations
109	Improving access to medicines: empowering patients in the quest to improve treatment for rare lethal diseases. Journal of Medical Ethics, 2015, 41, 987-989.	1.8	8
110	TARDBP pathogenic mutations increase cytoplasmic translocation of TDP-43 and cause reduction of endoplasmic reticulum Ca2+ signaling in motor neurons. Neurobiology of Disease, 2015, 75, 64-77.	4.4	45
111	The longitudinal cerebrospinal fluid metabolomic profile of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 456-463.	1.7	49
112	Dominant, toxic gain-of-function mutations ingarslead to non-cell autonomous neuropathology. Human Molecular Genetics, 2015, 24, 4397-4406.	2.9	50
113	Neurofilament light chain. Neurology, 2015, 84, 2247-2257.	1.1	412
114	Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurology, The, 2015, 14, 883-892.	10.2	85
115	T₂-Weighted MRI Detects Presymptomatic Pathology in the SOD1 Mouse Model of ALS. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 785-793.	4.3	32
116	Expanding the genetics of huntingtonism. Neurology, 2014, 82, 286-287.	1.1	5
117	Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis. Brain, 2014, 137, 2546-2555.	7.6	151
118	An impedimetric assay of Î±-synuclein autoantibodies in early stage Parkinson's disease. RSC Advances, 2014, 4, 58773-58777.	3.6	18
119	Predictors of cognitive impairment in an early stage Parkinson's disease cohort. Movement Disorders, 2014, 29, 351-359.	3.9	124
120	Advances in the clinical science of the motor unit. Current Opinion in Neurology, 2014, 27, 503-505.	3.6	0
121	Swallowing and oropharyngeal dysphagia. Clinical Medicine, 2014, 14, 456.	1.9	2
122	Autosomal dominant inheritance of rapidly progressive amyotrophic lateral sclerosis due to a truncation mutation in the fused in sarcoma (FUS) gene. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 557-562.	1.7	15
123	Comprehensive morphometry of subcortical grey matter structures in earlyâ€stage Parkinson's disease. Human Brain Mapping, 2014, 35, 1681-1690.	3.6	84
124	Chondrolectin affects cell survival and neuronal outgrowth in in vitro and in vivo models of spinal muscular atrophy. Human Molecular Genetics, 2014, 23, 855-869.	2.9	62
125	Advances in motor neurone disease. Journal of the Royal Society of Medicine, 2014, 107, 14-21.	2.0	93
126	Neuromuscular junction maturation defects precede impaired lower motor neuron connectivity in Charcot-Marie-Tooth type 2D mice. Human Molecular Genetics, 2014, 23, 2639-2650.	2.9	75

#	Article	IF	Citations
127	A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions inC9orf72reveals marked differences in results among 14 laboratories. Journal of Medical Genetics, 2014, 51, 419-424.	3.2	118
128	REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 560-566.	1.9	150
129	Overexpression of survival motor neuron improves neuromuscular function and motor neuron survival in mutant SOD1 mice. Neurobiology of Aging, 2014, 35, 906-915.	3.1	39
130	Progressive hemiparesis (Mills syndrome) with aphasia in amyotrophic lateral sclerosis. Neurology, 2014, 82, 457-458.	1.1	15
131	Amyotrophic lateral sclerosis: cell vulnerability or system vulnerability?. Journal of Anatomy, 2014, 224, 45-51.	1.5	32
132	Exome-wide Rare Variant Analysis Identifies TUBA4A Mutations Associated with Familial ALS. Neuron, 2014, 84, 324-331.	8.1	308
133	FTLD-ALS of TDP-43 type and SCA2 in a family with a full ataxin-2 polyglutamine expansion. Acta Neuropathologica, 2014, 128, 597-604.	7.7	23
134	The influence of age and gender on motor and non-motor features of early Parkinson's disease: Initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. Parkinsonism and Related Disorders, 2014, 20, 99-105.	2.2	223
135	Should all patients with ALS have genetic testing?. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 475-475.	1.9	5
136	SMA-EUROPE workshop report: opportunities and challenges in developing clinical trials for spinal muscular atrophy in Europe. Orphanet Journal of Rare Diseases, 2013, 8, 44.	2.7	17
137	Unmasking of incipient amyotrophic lateral sclerosis by botulinum toxin therapy. Journal of Neurology, 2013, 260, 1166-1167.	3.6	7
138	Progressive ataxia and palatal tremor associated with dense pontine calcification: A unique case. Movement Disorders, 2013, 28, 1155-1157.	3.9	5
139	Assessing social isolation in motor neurone disease: A Rasch analysis of the MND Social Withdrawal Scale. Journal of the Neurological Sciences, 2013, 334, 112-118.	0.6	8
140	Management of sialorrhoea in motor neuron disease: A survey of current UK practice. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 521-527.	1.7	28
141	Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurology, The, 2013, 12, 310-322.	10.2	454
142	A Loss-of-Function Variant in the Human Histidyl-tRNA Synthetase (HARS) Gene is Neurotoxic In Vivo. Human Mutation, 2013, 34, 191-199.	2.5	104
143	Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2013, 12, 339-345.	10.2	118
144	Mimics and chameleons in motor neurone disease. Practical Neurology, 2013, 13, 153-164.	1.1	84

#	Article	IF	Citations
145	Next generation sequencing for molecular diagnosis of neurological disorders using ataxias as a model. Brain, 2013, 136, 3106-3118.	7.6	146
146	Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS. Neurology, 2013, 80, 610-615.	1.1	50
147	Myelin imaging in amyotrophic and primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 562-573.	1.7	59
148	Autoimmune disease preceding amyotrophic lateral sclerosis. Neurology, 2013, 81, 1222-1225.	1.1	156
149	The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 666-673.	1.9	43
150	The impact of fatigue and psychosocial variables on quality of life for patients with motor neuron disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 537-545.	1.7	31
151	An Eye-Tracking Version of the Trail-Making Test. PLoS ONE, 2013, 8, e84061.	2.5	21
152	Cardiovascular fitness as a risk factor for amyotrophic lateral sclerosis: indirect evidence from record linkage study: Table 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 395-398.	1.9	62
153	Fractional Anisotropy in the Posterior Limb of the Internal Capsule and Prognosis in Amyotrophic Lateral Sclerosis. Archives of Neurology, 2012, 69, 1493.	4.5	60
154	Motor neurone disease is a clinical diagnosis. Practical Neurology, 2012, 12, 396-397.	1.1	6
155	Systematic review of methodology used in ultrasound studies aimed at creating charts of fetal size. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 1425-1439.	2.3	119
156	Magnetic resonance imaging of pathological processes in rodent models of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 288-301.	2.1	8
157	Protocol for diaphragm pacing in patients with respiratory muscle weakness due to motor neurone disease (DiPALS): a randomised controlled trial. BMC Neurology, 2012, 12, 74.	1.8	7
158	A calm before the exome storm. Neurology, 2012, 78, 1706-1707.	1.1	6
159	Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurology, The, 2012, 11, 323-330.	10.2	1,039
160	A Recurrent loss-of-function alanyl-tRNA synthetase (AARSâ€‰) mutation in patients with charcot-marie-tooth disease type 2N (CMT2N). Human Mutation, 2012, 33, 244-253.	2.5	90
161	Heterotopic pregnancy. Journal of Obstetrics and Gynaecology, 2011, 31, 7-12.	0.9	109
162	HspB8 mutation causing hereditary distal motor neuropathy impairs lysosomal delivery of autophagosomes. Journal of Neurochemistry, 2011, 119, 1155-1161.	3.9	49

#	Article	IF	Citations
163	Development of a patient reported outcome measure for fatigue in motor neurone disease: the Neurological Fatigue Index (NFI-MND). Health and Quality of Life Outcomes, 2011, 9, 101.	2.4	31
164	Rasch analysis of the hospital anxiety and depression scale (hads) for use in motor neurone disease. Health and Quality of Life Outcomes, 2011, 9, 82.	2.4	96
165	Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis. Brain, 2011, 134, 3470-3479.	7.6	229
166	Reversible molecular pathology of skeletal muscle in spinal muscular atrophy. Human Molecular Genetics, 2011, 20, 4334-4344.	2.9	89
167	Concordance between site of onset and limb dominance in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 853-854.	1.9	114
168	Oculomotor Dysfunction in Amyotrophic Lateral Sclerosis. Archives of Neurology, 2011, 68, 857.	4.5	112
169	The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy. DMM Disease Models and Mechanisms, 2011, 4, 457-467.	2.4	113
170	Familial versus sporadic amyotrophic lateral sclerosis--a false dichotomy?. Brain, 2011, 134, 3429-3434.	7.6	22
171	Catastrophic hyperkalaemia following administration of suxamethonium chloride to a patient with undiagnosed amyotrophic lateral sclerosis. Clinical Medicine, 2011, 11, 292-293.	1.9	10
172	Charcot-Marie-Toothâ€"Linked Mutant GARS Is Toxic to Peripheral Neurons Independent of Wild-Type GARS Levels. PLoS Genetics, 2011, 7, e1002399.	3.5	109
173	Compound Heterozygosity for Loss-of-Function Lysyl-tRNA Synthetase Mutations in a Patient with Peripheral Neuropathy. American Journal of Human Genetics, 2010, 87, 560-566.	6.2	169
174	Novel SPG11 mutations in Asian kindreds and disruption of spatacsin function in the zebrafish. Neurogenetics, 2010, 11, 379-389.	1.4	26
175	Review: Neuromuscular synaptic vulnerability in motor neurone disease: amyotrophic lateral sclerosis and spinal muscular atrophy. Neuropathology and Applied Neurobiology, 2010, 36, 133-156.	3.2	123
176	Robustness Testing against Low Voltage Transients - A Novel Approach. , 2010, , .		3
177	PATU5 Characterisation of fused in sarcoma pathology and FUS mutations in juvenile amyotrophic lateral sclerosis with basophilic inclusions. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e25-e25.	1.9	0
178	Pre-symptomatic development of lower motor neuron connectivity in a mouse model of severe spinal muscular atrophy. Human Molecular Genetics, 2010, 19, 420-433.	2.9	98
179	SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy. Human Molecular Genetics, 2010, 19, 4216-4228.	2.9	105
180	Dismutase-competent SOD1 mutant accumulation in myelinating Schwann cells is not detrimental to normal or transgenic ALS model mice. Human Molecular Genetics, 2010, 19, 815-824.	2.9	52

#	Article	IF	Citations
181	Reduction of elevated IGF-1 levels in coincident amyotrophic lateral sclerosis and acromegaly. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 255-257.	2.1	1
182	Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. Neurology, 2010, 75, 1645-1652.	1.1	257
183	The role of RNA processing in the pathogenesis of motor neuron degeneration. Expert Reviews in Molecular Medicine, 2010, 12, e21.	3.9	29
184	POMD09 Understanding the early pathological pathways in Parkinson's disease. The Oxford Parkinson's Disease Centre. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e59-e59.	1.9	0
185	Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology, 2010, 75, 611-618.	1.1	178
186	Do twin studies still have anything to teach us about the genetics of amyotrophic lateral sclerosis?. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1299-1300.	1.9	3
187	Head and other physical trauma requiring hospitalisation is not a significant risk factor in the development of ALS. Journal of the Neurological Sciences, 2010, 288, 45-48.	0.6	48
188	The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2010, 294, 81-85.	0.6	87
189	GARS axonopathy: not every neuron's cup of tRNA. Trends in Neurosciences, 2010, 33, 59-66.	8.6	70
190	Pattern of spread and prognosis in lower limb-onset ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 369-373.	2.1	58
191	TARDBP in amyotrophic lateral sclerosis: identification of a novel variant but absence of copy number variation. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1283-1285.	1.9	28
192	A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. Human Molecular Genetics, 2009, 18, 1524-1532.	2.9	106
193	An ENU-induced mutation in mouse glycyl-tRNA synthetase (GARS) causes peripheral sensory and motor phenotypes creating a model of Charcot-Marie-Tooth type 2D peripheral neuropathy. DMM Disease Models and Mechanisms, 2009, 2, 359-373.	2.4	91
194	Alternative Splicing Events Are a Late Feature of Pathology in a Mouse Model of Spinal Muscular Atrophy. PLoS Genetics, 2009, 5, e1000773.	3.5	210
195	Another gene for ALS. Neurology, 2009, 73, 1172-1173.	1.1	11
196	Survival motor neuron deficiency enhances progression in an amyotrophic lateral sclerosis mouse model. Neurobiology of Disease, 2009, 34, 511-517.	4.4	62
197	Biomarkers in amyotrophic lateral sclerosis. Lancet Neurology, The, 2009, 8, 94-109.	10.2	391
198	Investigation of white matter pathology in ALS and PLS using tractâ€based spatial statistics. Human Brain Mapping, 2009, 30, 615-624.	3.6	123

#	Article	IF	Citations
199	Motor neuron disease: THE BARE ESSENTIALS. Practical Neurology, 2009, 9, 303-309.	1.1	115
200	Functional vitamin B12 deficiency. Practical Neurology, 2009, 9, 37-45.	1.1	33
201	Progressive unsteadiness in a 68-year-old man with longstanding abdominal pain and altered bowel habit. Practical Neurology, 2009, 9, 210-220.	1.1	4
202	Primary angiitis of the CNS mimicking a spinal cord tumour. Journal of Neurology, 2008, 255, 1970-1972.	3.6	4
203	Asymmetrical late onset motor neuropathy associated with a novel mutation in the small heat shock protein HSPB1 (HSP27). Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 461-463.	1.9	41
204	TDP-43 expression in mouse models of amyotrophic lateral sclerosis and spinal muscular atrophy. BMC Neuroscience, 2008, 9, 104.	1.9	55
205	Candidate screening of the bovine and feline spinal muscular atrophy genes reveals no evidence for involvement in human motor neuron disorders. Neuromuscular Disorders, 2008, 18, 394-397.	0.6	7
206	Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Progress in Neurobiology, 2008, 85, 94-134.	5.7	435
207	Activation of mutant protein kinase CÎ³ leads to aberrant sequestration and impairment of its cellular function. Biochemical and Biophysical Research Communications, 2008, 372, 447-453.	2.1	9
208	Is Good Housekeeping the Key to Motor Neuron Survival?. Cell, 2008, 133, 572-574.	28.9	14
209	Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Human Molecular Genetics, 2008, 17, 949-962.	2.9	333
210	A case of celiac disease mimicking amyotrophic lateral sclerosis. Nature Clinical Practice Neurology, 2007, 3, 581-584.	2.5	26
211	Magnetic resonance spectroscopic imagingâ€"of prognostic value in amyotrophic lateral sclerosis?. Nature Clinical Practice Neurology, 2007, 3, 76-77.	2.5	1
212	Genetics of sporadic amyotrophic lateral sclerosis. Human Molecular Genetics, 2007, 16, R233-R242.	2.9	145
213	Chapter 7 Spinal muscular atrophies and hereditary motor neuropathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 82, 141-153.	1.8	3
214	The study of rare diseases: butterfly collecting or an entree to understanding common conditions?. Practical Neurology, 2007, 7, 210-211.	1.1	3
215	Crystal structure of human wildtype and S581L-mutant glycyl-tRNA synthetase, an enzyme underlying distal spinal muscular atrophy. FEBS Letters, 2007, 581, 2959-2964.	2.8	28
216	Murray Valley encephalitis in an adult traveller complicated by long-term flaccid paralysis: case report and review of the literature. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, 101, 284-288.	1.8	19

#	Article	IF	Citations
217	Neuromuscular disorders: therapeutic advances. Lancet Neurology, The, 2007, 6, 18-19.	10.2	1
218	The molecular genetics of non-ALS motor neuron diseases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 986-1000.	3.8	41
219	Treatment of vasculitic peripheral neuropathy: a retrospective analysis of outcome. QJM - Monthly Journal of the Association of Physicians, 2006, 100, 41-51.	0.5	59
220	Recent advances in the genetics of amyotrophic lateral sclerosis and frontotemporal dementia: common pathways in neurodegenerative disease. Human Molecular Genetics, 2006, 15, R182-R187.	2.9	81
221	A mutation in the small heat-shock protein HSPB1 leading to distal hereditary motor neuronopathy disrupts neurofilament assembly and the axonal transport of specific cellular cargoes. Human Molecular Genetics, 2006, 15, 347-354.	2.9	138
222	Severe childhood SMA and axonal CMT due to anticodon binding domain mutations in the GARS gene. Neurology, 2006, 67, 1710-1712.	1.1	72
223	Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy. Nature Genetics, 2004, 36, 597-601.	21.4	395
224	Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nature Genetics, 2004, 36, 602-606.	21.4	541
225	Vitamin E deficiency induced neurological disease in common variable immunodeficiency: two cases and a review of the literature of vitamin E deficiency. Clinical Immunology, 2004, 112, 24-29.	3.2	67
226	Motor neuron disease. Medicine, 2004, 32, 105-107.	0.4	2
227	Musculoskeletal diseases: from complex genetics to therapy. Current Opinion in Pharmacology, 2003, 3, 277-279.	3.5	0
228	Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy. Neuromuscular Disorders, 2003, 13, 357-364.	0.6	83
229	Spinal muscular atrophies reveal motor neuron vulnerability to defects in ribonucleoprotein handling. Current Opinion in Neurology, 2003, 16, 595-599.	3.6	17
230	Chapter 16 Spinal Muscular Atrophy. Blue Books of Practical Neurology, 2003, 28, 401-cp2.	0.1	1
231	Motor neurone disease. Postgraduate Medical Journal, 2002, 78, 513-519.	1.8	92
232	Normal d-dimer levels do not exclude the diagnosis of cerebral venous sinus thrombosis. Journal of Neurology, 2002, 249, 1603-1604.	3.6	27
233	Spinal Muscular Atrophy. Seminars in Neurology, 2001, 21, 189-198.	1.4	68
234	Screwdriver Headache: A Case of Traumatic Intracranial Hypotension. Clinical Radiology, 2001, 56, 676-680.	1.1	13

#	Article	IF	Citations
235	Characterisation of novel point mutations in the survival motor neuron gene SMN , in three patients with SMA. Human Genetics, 2001, 108, 356-357.	3.8	29
236	Spinal muscular atrophy. Journal of Inherited Metabolic Disease, 1999, 22, 545-554.	3.6	33
237	Characterization of a gene encoding survival motor neuron (SMN)-related protein, a constituent of the spliceosome complex. Human Molecular Genetics, 1998, 7, 2149-2156.	2.9	64
238	Missense mutation clustering in the survival motor neuron gene: a role for a conserved tyrosine and glycine rich region of the protein in RNA metabolism?. Human Molecular Genetics, 1997, 6, 497-500.	2.9	145
239	Genomic Organization and Chromosomal Localization of a Member of the MAP Kinase Phosphatase Gene Family to Human Chromosome 11p15.5 and a Pseudogene to 10q11.2. Genomics, 1997, 42, 284-294.	2.9	15
240	Gene conversion at the SMN locus in autosomal recessive spinal muscular atrophy does not predict a mild phenotype. Neuromuscular Disorders, 1997, 7, 198-201.	0.6	28
241	What's new in the molecular genetics of spinal muscular atrophy?. European Journal of Paediatric Neurology, 1997, 1, 149-155.	1.6	2
242	Gene deletions in spinal muscular atrophy.. Journal of Medical Genetics, 1996, 33, 93-96.	3.2	77
243	Molecular Genetics of Autosomal Recessive Spinal Muscular Atrophy. Molecular Medicine, 1996, 2, 400-404.	4.4	3
244	Evidence for compound heterozygosity causing mild and severe forms of autosomal recessive spinal muscular atrophy.. Journal of Medical Genetics, 1996, 33, 1019-1021.	3.2	4
245	Molecular genetics of autosomal recessive spinal muscular atrophy. Molecular Medicine, 1996, 2, 400-4.	4.4	1
246	Deletions in the survival motor neuron gene on 5q13 in autosomal recessive spinal muscular atrophy. Human Molecular Genetics, 1995, 4, 631-634.	2.9	233
247	Vasoactive intestinal peptide, but not pituitary adenylate cyclase-activating peptide, modulates the responsiveness of the gonadotroph to LHRH in man. Journal of Endocrinology, 1993, 137, 529-532.	2.6	30
248	Motor disorders. , 0, , 63-78.		0
249	Genome-Wide Analyses Identify KIF5A as a Novel ALS Gene. SSRN Electronic Journal, 0, , .	0.4	4
250	ALS Mice Carrying Pathological Mutant TDP-43, But Not Mutant FUS, Display Axonal Transport Defects <i>in vivo</i>. SSRN Electronic Journal, 0, , .	0.4	1